Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. - Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL (Leukemia & lymphoma, 2020)